Longevity Lab Report

Claim review

BPC-157: The Most Searched Peptide We Grade Has No Efficacy Trial, Only a Two-Person Safety Pilot

What the Wolverine peptide is, why regulators moved on it twice in 2026, and why none of that movement is evidence it works.

Saved articles

Ask ChatGPT about this article ↗

Copy the prompt, then paste it into ChatGPT to explore the findings and sources.

Open ChatGPT ↗

The findings

BPC-157 draws about 301,000 searches a month and grades D in our library, the lowest mark we give, because no published human randomized or efficacy trial stands behind it: no established dose, no efficacy data in people, and a safety file of one two-person uncontrolled pilot from 2025. Every claim for it rests on animal studies and testimonials.

BPC-157 is the most searched compound in our graded library, at about 301,000 searches a month. It is also the clearest case in the library of demand running ahead of evidence, so the first line of this check is the whole finding: there is no published human randomized or efficacy trial of BPC-157. The entire published human file is one two-person uncontrolled intravenous safety pilot from 2025, which tested no benefit.

What it is, and where the claims come from

BPC-157 is a synthetic peptide fragment derived from a protein found in stomach juice. In animal studies, mostly in rats, it has shown effects on tissue repair, blood vessel growth, and gut healing. Online, it circulates as a healing compound for tendons, joints, and the gut, sometimes under the nickname "the Wolverine peptide." Products are sold as injections and capsules by online sellers.

The gap between the animal record and the human claims is where every BPC-157 claim lives. Animal data does not transfer to humans at any fixed rate, and for this compound the transfer has never been tested for any benefit: no published human dose-finding, no human efficacy data, and a human safety record consisting of that one two-person uncontrolled pilot. Its grade in our library is D, with a worth-it grade of D at a typical $30 to $60 a month, because there is no human efficacy evidence to grade up from.

The 2026 regulatory movement, and what it is not

Two things happened in 2026 that sellers cite as momentum. In February, an HHS announcement moved BPC-157 toward Category 1, the compounding-eligible category, which would let compounding pharmacies prepare it with a prescription. In July, the FDA's Pharmacy Compounding Advisory Committee voted to recommend it for the 503A Bulks List, a non-binding recommendation made over the objection of the agency's own scientists.

Neither event is FDA approval, and neither says anything about whether BPC-157 works. Compounding categories govern whether a pharmacy may prepare a substance. They are not efficacy findings, and in this case the advisory vote went against the reviewing scientists' position. A claim that regulators are "approving" BPC-157 takes two procedural steps and mislabels both.

What a reader can actually conclude

Three facts hold up: the animal literature is real and extensive, and it is the entire efficacy file; the human safety picture rests on a single two-person pilot, which makes it neither reassuring nor alarming, with online products unregulated and of unknown purity; and BPC-157 is banned by WADA, so competitive athletes risk a sanction for a compound with no human efficacy evidence behind it.

Our standing rule for compounds like this one is simple: it is never suggested here, only verdicted. If a human efficacy trial of BPC-157 publishes, the record will be re-graded on it. The 2025 pilot is a safety note, not that trial. Until then, $30 to $60 a month buys a rat literature and a testimonial feed.

Peptides mentioned

Grades are research summaries, not medical advice. Decisions about your own health belong with your clinician.

Keep exploring

View all

The weekly newsletter

Keep up with what’s changing.

New research, useful tools, and the people shaping health and longevity. Selected and explained in one email.

See what you’ll receive ↗

Free. Confirm your email to subscribe. Unsubscribe anytime.